Invion(ASX) IVX

Market CapA$4.15M

Since IPO (2010)-100%

5 YearN/A

1 Year-71%

1 Month+0%

A$0.04

-5.00%

-0.00Today

Invion last closing stock price
Metric	Price	Date
Last close	AUD 0.04	2026-09-08

Invion stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+5.56%	AUD 0.04	2026-09-01
1 month	+0%	AUD 0.04	2026-08-07
3 month	-19.15%	AUD 0.05	2026-06-10
Year to date	-59.14%	AUD 0.09	2025-12-30
1 year	-70.77%	AUD 0.13	2025-09-08
Since inception	-99.85%	AUD 26.61	2010-02-15

Invion Financials at a Glance

Market Cap

A$4.15M

Revenue (TTM)

A$384.71K

Net Income (TTM)

-A$14.44M

EPS (TTM)

-A$0.06

P/E Ratio

-0.61

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.04

Volume

4,929

Open

A$0.04

Price

A$0.04

Volume

4,929

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.03 - A$0.13

Estimated Earnings Date

Feb 26, 2026

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.04

Volume

4,929

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.03 - A$0.13

Estimated Earnings Date

Feb 26, 2026

IVX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Invion

Invion Limited is an Australian clinical-stage life sciences company focused on developing innovative photodynamic therapy (PDT) solutions for various cancer types. The company's flagship product, IVX-PDT, aims to treat skin cancers and solid tumors, leveraging a strategic partnership with the Hudson Institute of Medical Research.

Products and Services

IVX-PDT: A photosensitizer agent targeting skin and solid tumors
Research collaboration with the Hudson Institute for advanced cancer treatments
Dedicated research agreement with Peter MacCallum Cancer Centre for ano-genital cancers

Growth Outlook

Partnerships with leading research institutions enhance R&D capabilities
Focus on expanding treatment applications for IVX-PDT across cancer types
Potential for significant market impact as PDT gains recognition in oncology

Financial Highlights

Recent quarterly revenue of AUD 2,228,435, indicating growth potential
Trailing twelve months (TTM) cash and short-term investments of AUD 1,375,430
Operating expenses for the latest quarter totaled AUD 2,572,731, reflecting ongoing investment in R&D

Invion Limited is positioned in the healthcare sector, specifically within drug manufacturing for specialty and generic applications. The company has made significant strides in its research and development efforts, particularly in photodynamic therapy, which is gaining traction as a viable treatment option for various cancers. The strategic alliances with reputable research institutions not only bolster Invion's credibility but also enhance its potential for innovation and market penetration. The financial data indicates a commitment to growth, with recent revenue figures suggesting a positive trajectory. The ongoing investment in research and development underscores the company's dedication to advancing its product offerings. As the healthcare landscape evolves, Invion Limited's focus on cutting-edge cancer therapies may present opportunities for future growth and expansion in the oncology market.

AI Generated • Aug 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Thian Chew, MBA

Website

www.inviongroup.com

Headquarters

Melbourne, VIC 3000, AU

IVX Financials

Key Financial Metrics (TTM)

Gross Margin

-347.68%

Operating Margin

-1472.22%

Net Income Margin

-1464.23%

Return on Equity

-102.18%

Return on Capital

-57.38%

Return on Assets

-68.97%

Earnings Yield

-1.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$4.15M

Shares Outstanding

109.20M

Volume

4.93K

Avg. Volume

71.24K

Financials (TTM)

Gross Profit

-A$2.63M

Operating Income

-A$10.95M

EBITDA

-A$7.94M

Operating Cash Flow

-A$5.34M

Capital Expenditure

-A$4.11K

Free Cash Flow

-A$5.35M

Cash & ST Invst.

A$592.31K

Total Debt

A$1.55M

Invion Performance Analysis

Invion annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-06-30	AUD 4,104,711	24.7%
2024	2024-06-30	AUD 3,694,256	-10.0%
2025	2025-06-30	AUD 0	N/A
2026	2026-06-30	AUD 384,707	N/A

Invion sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-31	-100.0%
Q4	2025-06-30	N/A
Q2	2025-12-31	N/A
Q4	2026-06-30	N/A

Invion annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-06-30	AUD -0.03	-32.4%
2024	2024-06-30	AUD -0.09	252.0%
2025	2025-06-30	AUD -0.12	38.9%
2026	2026-06-30	AUD -0.06	-48.8%

Invion sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-31	63.7%
Q4	2025-06-30	-225.5%
Q2	2025-12-31	53.9%
Q4	2026-06-30	49.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

A$384.71K

-73.8%

Gross Profit

-A$477.99K

-234.3%

Gross Margin

-1.24%

N/A

Market Cap

A$4.15M

N/A

Market Cap/Employee

A$518.70K

N/A

Employees

N/A

Net Income

-A$2.07M

+57.9%

EBITDA

-A$1.32M

+70.8%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

A$592.31K

-24.4%

Total Debt

A$1.55M

N/A

Accounts Receivable

A$0.00

-100.0%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$1.55M

N/A

Return on Assets

-68.97%

N/A

Return on Invested Capital

-1.06%

N/A

Free Cash Flow

-A$1.11M

+4.3%

Operating Cash Flow

-A$1.10M

+4.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PER.AXPercheron Therapeutics Limited

PER.AXPercheron Therapeutics LimitedA$0.00-33.33%

BGT.AXBio-Gene Technology Limited

BGT.AXBio-Gene Technology LimitedA$0.02+0.00%

CAN.AXCann Group Limited

CAN.AXCann Group LimitedA$0.01+0.00%

BIT.AXBiotron Limited

BIT.AXBiotron LimitedA$0.00-20.00%

HIQ.AXHITIQ Limited

HIQ.AXHITIQ LimitedA$0.01+20.00%

ADR.AXAdherium Limited

ADR.AXAdherium LimitedA$0.10+0.00%

ACR.AXAcrux Limited

ACR.AXAcrux LimitedA$0.01+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$46.34-0.10%

NOKNokia

NOKNokia$10.03+0.03%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$117.28+0.10%

INTCIntel

INTCIntel$95.80+0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.18-0.00%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$72.37+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.15-0.12%

Questions About IVX

What is the current price of Invion?

Invion is trading at A$0.04 per share.

What is the 52-week range for Invion?

Over the past 52 weeks, Invion has traded between A$0.03 and A$0.13.

How much debt does Invion have?

As of the most recent reporting period, Invion reported total debt of A$1.55M.

How much cash does Invion have on hand?

Invion reported A$592.31K in cash and cash equivalents in its most recent financial results.

What is Invion’s dividend yield?

Invion does not currently have a dividend yield.

Invion(ASX) IVX

Invion Financials at a Glance

IVX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Invion

IVX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Invion Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IVX

What is the current price of Invion?

What is the 52-week range for Invion?

How much debt does Invion have?

How much cash does Invion have on hand?

What is Invion’s dividend yield?

Premium Investing Services